• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于维奈克拉的疗法能否替代适合的老年急性髓系白血病患者的7+3诱导化疗？

Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?

作者信息

Foran James M

机构信息

Mayo Clinic Cancer Center, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

出版信息

Best Pract Res Clin Haematol. 2021 Dec;34(4):101335. doi: 10.1016/j.beha.2021.101335. Epub 2021 Nov 9.

DOI:10.1016/j.beha.2021.101335
PMID:34865692
Abstract

Older patients with acute myeloid leukemia (AML) face a dismal prognosis. Although venetoclax-based therapy has led to improved outcomes among unfit older patients with AML, it is not curative and its efficacy and long-term outcomes among fit older patients is unclear. This review provides insights into factors that influence treatment choices among older patients with AML and what we would need to know for venetoclax-based therapy to replace standard intensive 7 + 3 induction therapy.

摘要

老年急性髓系白血病（AML）患者预后不佳。尽管基于维奈克拉的疗法已使不适合强化疗的老年AML患者的预后得到改善，但该疗法并非治愈性疗法，且其在适合强化疗的老年患者中的疗效及长期预后尚不清楚。本综述深入探讨了影响老年AML患者治疗选择的因素，以及为使基于维奈克拉的疗法取代标准的7+3诱导强化疗，我们还需要了解哪些信息。

相似文献

1
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?基于维奈克拉的疗法能否替代适合的老年急性髓系白血病患者的7+3诱导化疗？
Best Pract Res Clin Haematol. 2021 Dec;34(4):101335. doi: 10.1016/j.beha.2021.101335. Epub 2021 Nov 9.
2
Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.基于维奈克拉的联合疗法用于治疗新诊断的急性髓系白血病。
Future Oncol. 2021 Aug;17(23):2989-3005. doi: 10.2217/fon-2021-0262. Epub 2021 May 24.
3
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.在常规实践中，维奈托克联合用药在不符合强化化疗条件的新诊断急性髓系白血病患者中诱导出高缓解率。
Am J Hematol. 2021 Jul 1;96(7):790-795. doi: 10.1002/ajh.26190. Epub 2021 Apr 29.
4
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.5-阿扎胞苷和 venetoclax 后首次完全缓解的急性髓系白血病的异基因造血细胞移植：一项多中心回顾性研究。
Ann Hematol. 2022 Feb;101(2):379-387. doi: 10.1007/s00277-021-04693-8. Epub 2021 Oct 9.
5
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
6
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.我们如何将维奈托克纳入急性髓系白血病的治疗方案中。
Cancer J. 2022;28(1):2-13. doi: 10.1097/PPO.0000000000000567.
7
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.先前接受过低甲基化剂治疗的继发性 AML 患者的一线治疗方法对其结局的影响。
J Hematol Oncol. 2022 Jan 29;15(1):12. doi: 10.1186/s13045-022-01229-z.
8
Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax.急性髓系白血病（AML）中的耐药机制：对介导维奈托克耐药的分子途径的见解
Best Pract Res Clin Haematol. 2021 Mar;34(1):101251. doi: 10.1016/j.beha.2021.101251. Epub 2021 Feb 6.
9
Venetoclax in acute myeloid leukemia - current and future directions.维奈托克治疗急性髓系白血病——现状与未来方向。
Leuk Lymphoma. 2020 Jun;61(6):1313-1322. doi: 10.1080/10428194.2020.1719098. Epub 2020 Feb 7.
10
A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.高危骨髓增生异常综合征和急性髓系白血病患者用维奈克拉治疗的真实土耳其经验。
Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):e686-e692. doi: 10.1016/j.clml.2021.04.004. Epub 2021 Apr 20.

引用本文的文献

1
Feasibility of allogeneic stem cell transplantation (HSCT) in patients with acute myeloid leukemia previously treated with CPX-351: report from a single center.接受过CPX-351治疗的急性髓性白血病患者进行异基因干细胞移植（HSCT）的可行性：来自单中心的报告
Ann Hematol. 2025 Jun 23. doi: 10.1007/s00277-025-06462-3.
2
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy.PIP4K2 抑制剂 THZ-P1-2 通过破坏线粒体动态平衡和自噬来发挥抗白血病活性。
Blood Cancer J. 2022 Nov 9;12(11):151. doi: 10.1038/s41408-022-00747-w.
3
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.
年龄 70 岁或以上、适合强化化疗的 AML 患者的评分系统：一项基于 DATAML、SAL 和 PETHEMA 登记处的大型欧洲数据集的研究。
Blood Cancer J. 2022 Jul 11;12(7):107. doi: 10.1038/s41408-022-00700-x.